Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis opens Cambridge research facility

Executive Summary

Novartis' $250 mil. investment in a 255,000 sq. ft. research facility in Cambridge, Mass. is part of the continuing trend of increasing R&D investments in the U.S. over Europe, company says. Sen. Edward Kennedy (D-Mass.) and Rep. Michael Capuano (D-Mass.) joined Novartis in a May 6 press conference announcing the opening. Research activities are scheduled to begin in the first quarter of 2003 with 400 employees, with an expansion planned to accommodate 900 scientists...

You may also be interested in...



Rx Industry’s Economic Value Should Preclude Price Controls, Novartis Says

The pharmaceutical industry is of "strategic value" to the U.S. economy and should not be jeopardized by instituting drug price controls, Novartis CEO Daniel Vasella, PhD, told the AARP International Forum on Prescription Drug Pricing Policy June 10 in Washington, D.C

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039829

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel